REG - Sareum Holdings PLC - Exercise of Warrants

Sareum HoldingsAnnouncement

01/05/2026 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA7714Ca&default-theme=true

RNS Number : 7714C  Sareum Holdings PLC  01 May 2026

Sareum Holdings plc

("Sareum" or the "Company")

Exercise of Warrants

Cambridge, UK, 1 May 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors for
autoimmune disease and cancer, announces that it has received notice to
exercise certain warrants to subscribe for a total of 500,000 new ordinary
shares in the capital of the Company at a price of 12.5 pence per ordinary
share ("New Ordinary Shares") for a total consideration to the Company of
£62,500.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange plc for the admission
of the 500,000 New Ordinary Shares to trading on AIM ("Admission"). It is
expected that Admission will occur at 8.00 a.m. (London time) on or around
Wednesday 6(th) May 2026.  The New Ordinary Shares will rank pari passu with
the existing ordinary shares.

Immediately following Admission, the total number of ordinary shares in issue
will be 138,565,173. and the total number of voting rights will therefore be
138,565,173, and this figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.

For Further Information:

 

 Sareum Holdings plc

 Stephen Parker, Executive Chairman                 01223 497700

                                                    ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                        020 7409 3494

 Singer Capital Markets (Joint Corporate Broker)

 Phil Davies                                        020 7496 3000

 Oberon Capital (Joint Corporate Broker)

 Mike Seabrook / Nick Lovering                      020 3179 5300

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Lisa Lam / Tom Daniel            020 3709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for certain haematological cancers and has recently initiated a
preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory
diseases such as multiple sclerosis and Parkinson's disease.

The Company also owns the license for SRA737, a clinical-stage Checkpoint
kinase 1 inhibitor that targets cancer cell replication and DNA damage repair
mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEASSFELLKEEA



            Copyright 2019 Regulatory News Service, all rights reserved